No Data
No Data
No Data
No Data
No Data
Alibaba Pictures expects year-on-year losses in the previous fiscal year to Yingxinda Biotech's product revenue increase by more than 60% in the first quarter|Selected Hong Kong Stock Announcements
① Alibaba Pictures expects to turn a year-on-year loss into a profit in the previous fiscal year. What is the revenue growth rate? ② Cinda Biotech's product revenue increased by more than 60% in the first quarter. What is the overall scale?
cls.cnMay 1 07:02
華潤醫藥:公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
Futu NewsApr 30 22:14 · Announcements
Hansoh Pharmaceutical's 2023 Profit Up 27%
Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s
MT NewswiresApr 30 18:17
Cinda Biotech (01801.HK): Total product revenue in the first quarter exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%
On April 30, Gelonghui | Cinda Biotech (01801.HK) announced that in the first quarter of 2024, the company achieved total product revenue exceeding RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Dabershu (Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products have accelerated growth and continued to increase their contribution.
Gelonghui FinanceApr 30 17:03
Yao Ming Kangde (02359.HK) spent 2005 million yuan to buy back 457,300 A shares on April 30
On April 30, Ge Longhui | Yao Ming Kangde (02359.HK) issued an announcement. On April 30, 2024, it spent RMB 2005 million yuan to repurchase 457,300 A shares, with a repurchase price of 43.57-44.7 yuan per share.
Gelonghui FinanceApr 30 16:54
Anectinib fumarate capsules, a Class 1 innovative drug independently developed by China Biopharmaceutical (01177), were approved for marketing
China Biopharmaceutical (01177) announced that the group's self-developed Class 1 innovative drug anectinil fumarate capsules “U...
Zhitong FinanceApr 30 16:35